News
Mission drives innovation, and innovation improves quality of life
News
-
Year-end Summary | TargetRx won multiple awards in 20202020-12-31 Views:131
The year 2020 is a very rewarding year, in which, the new drugs independently developed by TargetRx made breakthrough progress: the next-generation Bcr-Abl inhibitor TGRX-678 for treatment of CML and the ALK ROS1 dual inhibitor TGRX-326 for treatment of...
-
TargetRx's next-generation ALK inhibitor for NSCLC has been cleared for clinical trials in China2020-12-17 Views:150
On December 17, 2020, TGRX-326, a next-generation ALK ROS1 dual inhibitor independently developed by Shenzhen TargetRx Inc , has officially obtained the clinical trial notification issued by the Center for Drug Evaluation (CDE)... -
CDE has accepted the clinical application of TargetRx's TGRX-326, a next-generation ALK inhibitor for NSCLC2020-10-17 Views:177
On October 16, 2020, Centre for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) accepted the clinical application of TGRX-326, a potent next-generation inhibitor developed by Shenzhen TargetRx Inc ... -
TargetRx completed strategic financing of nearly 100 million yuan2020-09-18 Views:100
Recently, with the strong support of Hongtai Aplus, Shenzhen TargetRx Inc , a leading enterprise of targeted anti-cancer drugs, completed a round of strategic financing of nearly 100 million yuan... -
Dr. Yihan Wang attended Nanshan Doctor Forum2020-09-07 Views:63
Last week, Dr Yihan Wang, Chairman and CEO of TargetRx, was invited to attend the Nanshan Doctor Forum hosted by Nanshan District Association for Science and Technology and Nanshan Library, and undertaken by Nanshan Science and Technology Office... -
TargetRx's next-generation Bcr-Abl inhibitor used to treat CML has been cleared for clinical trials in China2020-06-04 Views:70
On June 3, 2020, the fourth-generation Bcr-Abl inhibitor TGRX-678 independently developed by Shenzhen TargetRx Inc was officially cleared for clinical trials via the notification issued by the Center for Drug Evaluation (CDE)...
Tel: +86-0755-86934300
3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
E-mail: 